Catheter-Mediated Selective Thrombolysis and Anticoagulant Therapy for Deep Vein Thrombosis: Analysis of Efficacy, Safety and Clinical Outcomes
Authors:
- Mehmet Cahit SaricaogluMSMehmet Cahit Saricaoglu
- Ali Ihsan HasdeAHAli Ihsan Hasde
- Ali Fuat KaracuhaAKAli Fuat Karacuha
- Ahmet KayanAKAhmet Kayan
- Onur BuyukcakirOBOnur Buyukcakir
- Fatma AkçaFAFatma Akça
- Evren OzcinarEOEvren Ozcinar
- Cagdas BaranCagdas Baran
- Mustafa Bahadir InanMIMustafa Bahadir Inan
- Mustafa SirlakMSMustafa Sirlak
- Levent YaziciogluLYLevent Yazicioglu
- Ahmet Ruchan AkarAAAhmet Ruchan Akar
Preprint
- 9 April 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background. Deep vein thrombosis (DVT) is an important component of venous thromboembolism and can lead to pulmonary embolism with high morbidity and mortality. Anticoagulant therapy alone (ACA) and catheter-mediated thrombolysis (CDT) are commonly used strategies for the management of DVT. Although CDT has been reported to be effective in reducing the risk of postthrombotic syndrome (PTS), it remains unclear in which patient groups it should be preferred due to the risk of bleeding.Methods. This retrospective study included 175 patients diagnosed with DVT between 2015 and 2024 (98 ACA, 77 CDT). Patients with a diagnosis of proximal DVT, aged ≥18 years and with at least 30 days of follow-up data were included. The primary endpoint was 30-day mortality and secondary endpoints were length of hospitalization, pulmonary embolism and bleeding complications. Results. The CDT group was superior to ACA in thrombus clearance rates, especially in iliac vein thrombosis (97.7% vs. 78%, p=0.003). Clinical symptoms improved faster in the CDT group, but total hospitalization was longer. There were no significant differences in bleeding complications and mortality rates between the two groups.Conclusion. The optimal approach to DVT treatment should be based on the patient's individual risk factors. Although CDT provides a higher thrombus clearance rate, especially in iliac vein thrombosis, it may not be suitable for all patients. Future large-scale studies will contribute to a better understanding of the long-term outcomes of interventional therapies.Keywords
All Related Versions
- Version 1, 2025-04-09, Preprints
- Published version: Journal of Clinical Medicine, 14 (10), 3298.
This publication has 13 references indexed in Scilit:
- Rationale and design of the DEFIANCE study: A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosisAmerican Heart Journal, 2024
- Global Health Burden of Venous ThromboembolismArteriosclerosis, Thrombosis, and Vascular Biology, 2024
- Antithrombotic Therapy for VTE DiseaseChest, 2024
- A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous ThromboembolismJournal of Clinical Medicine, 2024
- Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous ThrombosisEuropean Journal of Vascular and Endovascular Surgery, 2021
- The Attract Trial: A Step Forward for Evidence Based DVT CareEuropean Journal of Vascular and Endovascular Surgery, 2018
- Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein ThrombosisNew England Journal of Medicine, 2017
- Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trialThe Lancet Haematology, 2016
- Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation vs Anticoagulation Alone to Treat Lower-Extremity Proximal Deep Vein ThrombosisJAMA Internal Medicine, 2014
- Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trialThe Lancet, 2012